Vera Therapeutics, INC. 8-K Filing
Ticker: VERA · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2025 |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $40,000, $10,000, $400,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Vera Therapeutics, INC. (ticker: VERA) to the SEC on Nov 26, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (hich registered Class A common stock, $0.001 par value per share VERA The Nasdaq); $40,000 (also receive an annual cash retainer of $40,000 for his service on the Board, and $10,0); $10,000 (0,000 for his service on the Board, and $10,000 for his service on the Audit Committee,); $400,000 (grant date fair value of not more than $400,000, subject to his continuous service as o).
How long is this filing?
Vera Therapeutics, INC.'s 8-K filing is 3 pages with approximately 782 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 782 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2025-11-26 16:30:26
Key Financial Figures
- $0.001 — hich registered Class A common stock, $0.001 par value per share VERA The Nasdaq
- $40,000 — also receive an annual cash retainer of $40,000 for his service on the Board, and $10,0
- $10,000 — 0,000 for his service on the Board, and $10,000 for his service on the Audit Committee,
- $400,000 — grant date fair value of not more than $400,000, subject to his continuous service as o
Filing Documents
- vera-20251125.htm (8-K) — 44KB
- 0001193125-25-300647.txt ( ) — 147KB
- vera-20251125.xsd (EX-101.SCH) — 24KB
- vera-20251125_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vera Therapeutics, Inc. Date: November 26, 2025 By: /s/ Sean Grant Sean Grant Chief Financial Officer